Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solana Company (NASDAQ: HSDT) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and other required reports. These documents offer detailed insight into Solana Company’s dual focus as a neurotech medical device issuer and a Solana-centric digital asset treasury.
In its filings, Solana Company describes its operations in the electromedical and electrotherapeutic apparatus manufacturing industry and outlines its orally applied technology platform for neurologic deficits. Quarterly and annual reports, such as the Form 10-K and Form 10-Q, present financial statements, revenue components (including staking rewards and other revenue), operating expenses, research and development costs, and unrealized gains or losses on digital assets.
Current reports on Form 8-K document material events, including the name change from Helius Medical Technologies, Inc. to Solana Company, the adoption of a Solana-focused digital asset treasury, PIPE financings, warrant issuances, stock repurchase authorizations, changes in independent registered public accounting firms, and board and governance developments. Proxy materials on Schedule 14A describe matters submitted to stockholders, such as director elections, equity incentive plan amendments, and approvals related to cryptocurrency-linked warrants.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex items such as derivative liabilities tied to stapled warrants, digital asset treasury activities, or auditor changes. Users can review real-time updates from EDGAR, track quarterly (10-Q) and annual (10-K) reports, and examine Form 4 and related disclosures of insider transactions where available, all supported by concise AI explanations that clarify terminology and context.
Solana Company is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026 at 9:00 a.m. ET. Holders of its Class A common stock as of April 1, 2026, when 54,889,569 shares were outstanding, may vote.
Stockholders will elect seven directors and vote on ratifying CBIZ as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR Proposal 2.
The filing details board independence, leadership structure and committee assignments, and outlines executive pay. In 2025, CEO Dane Andreeff received total compensation of $2.1 million, CFO Jeffrey Mathiesen received $1.5 million, and Executive Chairman Joseph Chee received $6.9 million, including 1,109,118 RSUs tied to a 2025 private placement and digital asset treasury work. The proxy also describes change-in-control severance protections, a clawback policy for erroneously awarded compensation, and the company’s insider trading and board governance policies.
Solana Company appointed Agustina “Madelene” Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. She brings more than 25 years of global finance experience across crypto, fintech, and public companies, including senior roles at Hedera Hashgraph, Aptos Labs, Gemini, and JUUL Labs.
Under an Offer Letter dated March 13, 2026, she will receive a $350,000 annual base salary, be eligible for an annual target bonus equal to 40% of base salary, and additional equity incentives with a combined target value of $300,000 to $500,000. After three months, subject to board approval, she is also eligible for a one-time stock option grant with a grant date fair value of $75,000, vesting over four years.
Solana Co officer Tjandrasuwita Agustina Gani, listed as COO & Deputy CFO, has filed an insider ownership report for the company. The filing shows no insider stock transactions or derivative positions, indicating only the reporting of status as an officer without buy or sell activity.
Solana Co director Sherrie L. Perkins reported equity compensation awards. She received a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. She was also granted 2,180 shares of Class A Common Stock as restricted stock units under the 2022 Equity Incentive Plan. According to the awards’ terms, 75% of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, subject to her continued service. Following the stock grant, she directly holds 92,220 shares of Class A Common Stock.
Solana Co director Paul Buckman received new equity awards as part of his compensation. He was granted a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036.
He also received 2,180 shares of Class A Common Stock, increasing his direct holdings to 92,004 shares. Both the option and restricted stock units vest 75% on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, contingent on his continued service.
Solana Co director Edward M. Straw received equity awards as part of his compensation. He was granted stock options for 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock via restricted stock units. Seventy-five percent of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, conditional on his continued service. Following the stock grant, he directly holds 92,291 Class A Common shares.
Solana Co director Walter Blane received new equity awards in the form of stock options and restricted stock units. He was granted stock options covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock from a grant classified as a restricted stock unit award. According to the award terms, 75% of both the RSUs and the options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, if he continues in service.
Solana Company filed a Post-Effective Amendment No. 3 to its Form S-3 shelf registration to convert the filing to a non-automatic shelf and to register for resale up to 155,646,217 shares of Class A common stock previously issued in PIPE and related transactions. The prospectus covers (i) 38,049,663 PIPE Shares, (ii) 36,261,239 Pre-Funded Warrant Shares, (iii) 73,941,196 Stapled Warrant Shares, and (iv) 7,394,119 Advisor Shares. The company states the PIPE Offerings closed on September 18, 2025 and generated aggregate gross proceeds of approximately $500 million. The registration permits resale by the identified selling stockholders; the company will not receive proceeds from those resales. The prospectus also discloses an ATM program with aggregate sales capacity of $92.8 million and reports a Nasdaq last reported sale price of $1.86 per share on March 30, 2026.